US 8951972
FGFR1 extracellular domain combination therapies for lung cancer
granted A61KA61K2039/507A61K31/282
Quick answer
US patent 8951972 (FGFR1 extracellular domain combination therapies for lung cancer) held by Five Prime Therapeutics, Inc. expires Mon Feb 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Five Prime Therapeutics, Inc.
- Grant date
- Tue Feb 10 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 6
- CPC classes
- A61K, A61K2039/507, A61K31/282, A61K31/337, A61K31/365